Skip to main content
. 2017 Jun 1;27(3):121–129. doi: 10.1089/nat.2016.0650

FIG. 1.

FIG. 1.

Platelet levels over time in subjects with rheumatoid arthritis treated with ISIS 104838, which targets TNFα, in a 12-week, randomized, placebo-controlled phase 2 trial. Top panel shows the percent change from baseline and the bottom panel shows the absolute platelet count over time. Data lines represent dose group: − placebo, ··· 100 mg/week, − − 200 mg/week, and −·− 400 mg/week. Symbols represent individual subject data. Vertical gray lines indicate the first and last dose of the 12-week treatment period.